Metagenomi (MGX) Director Reid Laurence Buys Stock

What Happened
Reid Laurence, a director of Metagenomi Therapeutics, bought a total of 20,000 shares (19,883 + 117) in two open‑market purchases on September 9, 2026, for a combined reported value of $23,401. The filing reports a weighted average price of $1.17 per share (range: $1.165–$1.175).

Key Details

• Transaction date: 2026-09-09; Form 4 filed: 2026-09-11 (timely filing).
• Trades: 19,883 shares at a weighted avg $1.17 (total $23,263) and 117 shares at $1.18 (total $138).
• Total acquired: 20,000 shares for $23,401.
• Shares owned after transaction: Not disclosed in this Form 4.
• Footnote: Price reported is a weighted average; purchases occurred at prices between $1.165 and $1.175 (full per-price breakdown available to the SEC on request).
• Transaction code: P = Purchase.

Context
Purchases by directors are generally treated as a positive signal because they increase insider ownership, but filings alone don’t explain the insider’s motivation. This was a straightforward open‑market purchase (not an option exercise, gift, or tax withholding event).